13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market
1 Study Coverage
1.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Introduction
1.2 Market by Type
1.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Serotype 6B
1.2.3 7F Serotype
1.2.4 Serotype 9V
1.2.5 14 Serotype
1.2.6 Serotype 18C
1.2.7 Serotype 19A
1.2.8 19F Serotype
1.2.9 23F Serotype
1.2.10 24F Serotype
1.2.11 Other
1.3 Market by Application
1.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Infants from 6 Weeks to 15 Months Old
1.3.3 Children Aged 15 Months to 5 Years
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Estimates and Forecasts 2017-2028
2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Estimates and Forecasts 2017-2028
2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region
2.4.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2017-2022)
2.4.2 Global Sales 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Region (2023-2028)
2.5 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region
2.5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2017-2022)
2.5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Manufacturers
3.1.1 Global Top 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturers by Sales (2017-2022)
3.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in 2021
3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Manufacturers
3.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Manufacturers (2017-2022)
3.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue in 2021
3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
4.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Historical Sales by Type (2017-2022)
4.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecasted Sales by Type (2023-2028)
4.1.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)
4.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type
4.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Historical Revenue by Type (2017-2022)
4.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecasted Revenue by Type (2023-2028)
4.2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2017-2028)
4.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type
4.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2017-2022)
4.3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
5.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Historical Sales by Application (2017-2022)
5.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecasted Sales by Application (2023-2028)
5.1.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)
5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application
5.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Historical Revenue by Application (2017-2022)
5.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecasted Revenue by Application (2023-2028)
5.2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2017-2028)
5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application
5.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2017-2022)
5.3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price Forecast by Application (2023-2028)
6 North America
6.1 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Type
6.1.1 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)
6.1.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2028)
6.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Application
6.2.1 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)
6.2.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2028)
6.3 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country
6.3.1 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2028)
6.3.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Type
7.1.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)
7.1.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2028)
7.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Application
7.2.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)
7.2.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2028)
7.3 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country
7.3.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2028)
7.3.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Type
8.1.1 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)
8.1.2 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2028)
8.2 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Application
8.2.1 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)
8.2.2 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2028)
8.3 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Region
8.3.1 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2017-2028)
8.3.2 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Type
9.1.1 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)
9.1.2 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2028)
9.2 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Application
9.2.1 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)
9.2.2 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2028)
9.3 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country
9.3.1 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2028)
9.3.2 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Type
10.1.1 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)
10.1.2 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2028)
10.2 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Application
10.2.1 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)
10.2.2 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2028)
10.3 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country
10.3.1 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2028)
10.3.2 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 Minhai Bio
11.2.1 Minhai Bio Corporation Information
11.2.2 Minhai Bio Overview
11.2.3 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Minhai Bio Recent Developments
11.3 Kexing Bio
11.3.1 Kexing Bio Corporation Information
11.3.2 Kexing Bio Overview
11.3.3 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Kexing Bio Recent Developments
11.4 Cansino Bio
11.4.1 Cansino Bio Corporation Information
11.4.2 Cansino Bio Overview
11.4.3 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Cansino Bio Recent Developments
11.5 Lanzhou Biological Preparations Institute
11.5.1 Lanzhou Biological Preparations Institute Corporation Information
11.5.2 Lanzhou Biological Preparations Institute Overview
11.5.3 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Lanzhou Biological Preparations Institute Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industry Chain Analysis
12.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Mode & Process
12.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales and Marketing
12.4.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Channels
12.4.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors
12.5 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industry Trends
13.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Drivers
13.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Challenges
13.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints
14 Key Findings in The Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Serotype 6B
Table 3. Major Manufacturers of 7F Serotype
Table 4. Major Manufacturers of Serotype 9V
Table 5. Major Manufacturers of 14 Serotype
Table 6. Major Manufacturers of Serotype 18C
Table 7. Major Manufacturers of Serotype 19A
Table 8. Major Manufacturers of 19F Serotype
Table 9. Major Manufacturers of 23F Serotype
Table 10. Major Manufacturers of 24F Serotype
Table 11. Major Manufacturers of Other
Table 12. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 14. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2017-2022) & (K Units)
Table 15. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2017-2022)
Table 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2023-2028) & (K Units)
Table 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2023-2028)
Table 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2017-2022) & (US$ Million)
Table 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2017-2022)
Table 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2023-2028) & (US$ Million)
Table 21. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2023-2028)
Table 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Manufacturers (2017-2022) & (K Units)
Table 23. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Manufacturers (2017-2022)
Table 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Manufacturers (2017-2022)
Table 26. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Manufacturers (2017-2022) &(US$/Unit)
Table 27. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) as of 2021)
Table 29. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base Distribution and Headquarters
Table 30. Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offered
Table 31. Date of Manufacturers Enter into 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)
Table 34. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)
Table 35. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Type (2017-2022)
Table 36. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Type (2023-2028)
Table 37. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2022) & (US$ Million)
Table 38. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2023-2028) & (US$ Million)
Table 39. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Type (2017-2022)
Table 40. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Type (2023-2028)
Table 41. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2017-2022) & (US$/Unit)
Table 42. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price Forecast by Type (2023-2028) & (US$/Unit)
Table 43. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)
Table 44. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)
Table 45. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Application (2017-2022)
Table 46. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Application (2023-2028)
Table 47. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2022) & (US$ Million)
Table 48. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2023-2028) & (US$ Million)
Table 49. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Application (2017-2022)
Table 50. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Application (2023-2028)
Table 51. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2017-2022) & (US$/Unit)
Table 52. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price Forecast by Application (2023-2028) & (US$/Unit)
Table 53. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)
Table 54. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)
Table 55. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2022) & (US$ Million)
Table 56. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2023-2028) & (US$ Million)
Table 57. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)
Table 58. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)
Table 59. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2022) & (US$ Million)
Table 60. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2023-2028) & (US$ Million)
Table 61. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2022) & (K Units)
Table 62. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2023-2028) & (K Units)
Table 63. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2022) & (US$ Million)
Table 64. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2023-2028) & (US$ Million)
Table 65. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)
Table 66. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)
Table 67. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2022) & (US$ Million)
Table 68. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2023-2028) & (US$ Million)
Table 69. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)
Table 70. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)
Table 71. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2022) & (US$ Million)
Table 72. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2023-2028) & (US$ Million)
Table 73. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2022) & (K Units)
Table 74. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2023-2028) & (K Units)
Table 75. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2022) & (US$ Million)
Table 76. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2023-2028) & (US$ Million)
Table 77. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)
Table 78. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)
Table 79. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2022) & (US$ Million)
Table 80. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2023-2028) & (US$ Million)
Table 81. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)
Table 82. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)
Table 83. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2022) & (US$ Million)
Table 84. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2023-2028) & (US$ Million)
Table 85. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2017-2022) & (K Units)
Table 86. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2023-2028) & (K Units)
Table 87. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2017-2022) & (US$ Million)
Table 88. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2023-2028) & (US$ Million)
Table 89. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)
Table 90. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)
Table 91. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2022) & (US$ Million)
Table 92. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2023-2028) & (US$ Million)
Table 93. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)
Table 94. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)
Table 95. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2022) & (US$ Million)
Table 96. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2023-2028) & (US$ Million)
Table 97. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2022) & (K Units)
Table 98. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2023-2028) & (K Units)
Table 99. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2022) & (US$ Million)
Table 100. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2023-2028) & (US$ Million)
Table 101. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)
Table 102. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)
Table 103. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2022) & (US$ Million)
Table 104. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2023-2028) & (US$ Million)
Table 105. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)
Table 106. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)
Table 107. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2022) & (US$ Million)
Table 108. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2023-2028) & (US$ Million)
Table 109. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2022) & (K Units)
Table 110. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2023-2028) & (K Units)
Table 111. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2022) & (US$ Million)
Table 112. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2023-2028) & (US$ Million)
Table 113. Pfizer Corporation Information
Table 114. Pfizer Description and Major Businesses
Table 115. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 116. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Pfizer Recent Developments
Table 118. Minhai Bio Corporation Information
Table 119. Minhai Bio Description and Major Businesses
Table 120. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 121. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Minhai Bio Recent Developments
Table 123. Kexing Bio Corporation Information
Table 124. Kexing Bio Description and Major Businesses
Table 125. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 126. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Kexing Bio Recent Developments
Table 128. Cansino Bio Corporation Information
Table 129. Cansino Bio Description and Major Businesses
Table 130. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 131. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Cansino Bio Recent Developments
Table 133. Lanzhou Biological Preparations Institute Corporation Information
Table 134. Lanzhou Biological Preparations Institute Description and Major Businesses
Table 135. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 136. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Lanzhou Biological Preparations Institute Recent Developments
Table 138. Key Raw Materials Lists
Table 139. Raw Materials Key Suppliers Lists
Table 140. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors List
Table 141. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customers List
Table 142. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Trends
Table 143. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Drivers
Table 144. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Challenges
Table 145. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Picture
Figure 3. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Type in 2021 & 2028
Figure 3. Serotype 6B Product Picture
Figure 4. 7F Serotype Product Picture
Figure 5. Serotype 9V Product Picture
Figure 6. 14 Serotype Product Picture
Figure 7. Serotype 18C Product Picture
Figure 8. Serotype 19A Product Picture
Figure 9. 19F Serotype Product Picture
Figure 10. 23F Serotype Product Picture
Figure 11. 24F Serotype Product Picture
Figure 12. Other Product Picture
Figure 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Application in 2021 & 2028
Figure 14. Infants from 6 Weeks to 15 Months Old
Figure 15. Children Aged 15 Months to 5 Years
Figure 16. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Report Years Considered
Figure 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2017-2028 (K Units)
Figure 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2017-2028 (US$ Million)
Figure 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 21. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2017-2022)
Figure 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2023-2028)
Figure 23. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales YoY (2017-2028) & (K Units)
Figure 24. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales YoY (2017-2028) & (K Units)
Figure 26. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales YoY (2017-2028) & (K Units)
Figure 28. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue YoY (2017-2028) & (US$ Million)
Figure 29. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales YoY (2017-2028) & (K Units)
Figure 30. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue YoY (2017-2028) & (US$ Million)
Figure 31. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales YoY (2017-2028) & (K Units)
Figure 32. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue YoY (2017-2028) & (US$ Million)
Figure 33. The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 34. The Top 5 and 10 Largest Manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in the World: Market Share by 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue in 2021
Figure 35. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 36. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)
Figure 37. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2017-2028)
Figure 38. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)
Figure 39. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2017-2028)
Figure 40. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)
Figure 41. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2017-2028)
Figure 42. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)
Figure 43. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2017-2028)
Figure 44. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Country (2017-2028)
Figure 45. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Country (2017-2028)
Figure 46. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 47. Canada 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 48. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)
Figure 49. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2017-2028)
Figure 50. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)
Figure 51. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2017-2028)
Figure 52. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Country (2017-2028)
Figure 53. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Country (2017-2028)
Figure 54. Germany 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 55. France 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 56. U.K. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 57. Italy 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 58. Russia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 59. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)
Figure 60. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2017-2028)
Figure 61. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)
Figure 62. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2017-2028)
Figure 63. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Region (2017-2028)
Figure 64. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Region (2017-2028)
Figure 65. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 66. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 67. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 68. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 69. Australia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 70. China Taiwan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 71. Indonesia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 72. Thailand 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 73. Malaysia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 74. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)
Figure 75. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2017-2028)
Figure 76. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)
Figure 77. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2017-2028)
Figure 78. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Country (2017-2028)
Figure 79. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Country (2017-2028)
Figure 80. Mexico 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 81. Brazil 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 82. Argentina 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 83. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)
Figure 84. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2017-2028)
Figure 85. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)
Figure 86. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2017-2028)
Figure 87. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Country (2017-2028)
Figure 88. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Country (2017-2028)
Figure 89. Turkey 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 90. Saudi Arabia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 91. UAE 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (US$ Million)
Figure 92. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Value Chain
Figure 93. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Process
Figure 94. Channels of Distribution
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed
Industry Market Size
